Alignment Healthcare's Key California Plan Drops to 3.5 Stars in CMS 2027 Ratings
ALHC is trading near its 52-week low of $7.37 (6.4% below the low).
Summary
CMS released 2027 Medicare Advantage Star Ratings, and Alignment Healthcare's California H3815 HMO contract fell to 3.5 Stars, down from its prior 4-Star level. The H3815 contract serves approximately 75% of the company’s health plan membership. Six of the company's seven eligible contracts earned 4 Stars or higher, including three at 4.5 Stars, but the California plan is a major market and the drop is material. Management disputes the rating, calling it inconsistent with performance, and says it will pursue administrative remedies and litigation. The decline was driven by higher industry cut points and lower triple-weighted measures across HOS and Part D, and CMS retroactively eliminated bonus calculations for the Excellent Health Outcomes for All Index. Alignment expects the 3.5-Star rating for H3815 to impact 2028 quality bonus payments, with risk-sharing arrangements offsetting a portion, and plans administrative appeals and litigation. The 2027 Star results are not expected to impact revenue for fiscal years 2026 or 2027. The company believes these actions will position H3815 to return to at least a 4.0-Star rating in future rating years, with initiatives including enhancing member and provider engagement, expanding care gap closure programs, and providing additional quality oversight. This follows a September 15th 18% share drop to a 52-week low after a Baird conference presentation, and the stock is trading near that low. The rating decline could pressure 2027 enrollment and revenue in California, a core market.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Alignment expects the 3.5-Star rating for H3815 to impact 2028 quality bonus payments, with risk-sharing arrangements offsetting a portion, and plans administrative appeals and litigation.
- Membership and Causes
- H3815 contract serves approximately 75% of the company’s health plan membership.
- Decline driven by higher industry cut points and lower triple-weighted measures across HOS and Part D.
- CMS retroactively eliminated bonus calculations for the Excellent Health Outcomes for All Index.
- Revenue Impact — 2027 Star results are not expected to impact revenue for fiscal years 2026 or 2027.
- Future Rating Plans — Company believes actions will position H3815 to return to at least a 4.0-Star rating. Initiatives include enhancing member and provider engagement, expanding care gap closure programs, and providing additional quality oversight.
All 6 details
- H3815 contract serves approximately 75% of the company’s health plan membership.
- Decline driven by higher industry cut points and lower triple-weighted measures across HOS and Part D.
- CMS retroactively eliminated bonus calculations for the Excellent Health Outcomes for All Index.
- 2027 Star results are not expected to impact revenue for fiscal years 2026 or 2027.
- Company believes these actions will position H3815 to return to at least a 4.0-Star rating in future rating years.
- Initiatives include enhancing member and provider engagement, expanding care gap closure programs, and providing additional quality oversight.
- Membership and Causes
At the time of this announcement, ALHC was trading at $6.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.37 to $25.12. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.